652 results on '"Behrens, Frank"'
Search Results
52. Use of a “critical difference” statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritis
53. The need for comparative data in spondyloarthritis
54. Solar-Energie für alle.
55. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate.
56. Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.
57. Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting.
58. WSN COVERAGE IMPROVEMENT WITH ROF IN BUS TOPOLOGY FOR SMART CITIES
59. Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab
60. POS0881 Specific AI-Generated Pattern of Tender Joints and Tenderness at Enthesial Sites are Predictive for Objective Detection of Musculoskeletal Inflammation in Psoriasis Patients
61. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
62. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
63. Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis
64. Synthetic DMARDs
65. PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
66. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)
67. Fluorescence-optical imaging as a promising easy-to-use imaging biomarker to increase early psoriatic arthritis detection in patients with psoriasis: a cross-sectional cohort study with follow-up
68. An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study
69. Der Tierstil II im Merowingerreich
70. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
71. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
72. Correction to: Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study
73. Entwicklung eines unterstützenden Systems zur Befundanalyse und Versorgungsverbesserung bei Patienten mit Psoriasis Arthritis und axialer Spondylarthritis mithilfe von Künstliche Intelligenz- und Natural Language Processing-Methoden
74. Die 'ARIAA-Studie' – Abatacept verzögert den Übergang in eine RA bei at-risk-Patienten – klinische Ergebnisse zu Monat 18 der internationalen, randomisiert, placebo kontrollierten Studie
75. Real-world evidence on the use of GP2017 in patients with rheumatoid arthritis: Baseline characteristics and incidence of malignancies and mortality from German observational data
76. Ustekinumab-Immunogenität und der Einfluss von Methotrexat: Ergebnisse einer Post-hoc Analyse von Serumproben von Psoriasisarthritis Patienten einer randomisierten, doppelblinden, Multicenter-Studie
77. Impact of different classes of immune-suppressive treatments on the immune response before and after COVID booster vaccination
78. Add-on or withdrawal of methotrexate do not impact efficacy of IL12/23 inhibition in active PsA: Data from the multicenter investigator-initiated randomized placebo-controlled MUST trial
79. Vergleich von Patienten mit axialer Psoriasis-Arthritis mit axSpA-Patienten mit begleitender Psoriasis
80. Charakterisierung von Patient*innen mit Psoriasis-Arthritis in dermatologischer und rheumatologischer Versorgung: Eine Analyse zweier Krankheitsregister
81. Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
82. An objective, automated and robust scoring using fluorescence optical imaging to evaluate changes in micro-vascularisation indicating early arthritis
83. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1
84. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
85. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
86. Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational study
87. Replication of a distinct psoriatic arthritis risk variant at the IL23R locus
88. Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
89. Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial
90. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL)
91. Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
92. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
93. Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care
94. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
95. Therapiestrategien der Psoriasisarthritis
96. Comparison of cardiovascular risk burden in patients with psoriatic arthritis, ANCA-associated vasculitis and systemic lupus erythematosus
97. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
98. Fluorescence-optical imaging technique discriminates signs of early joint inflammation in patients suspect of Rheumatoid Arthritis in the PANORA trial
99. Development of quality standards for patients with axial spondyloarthritis for use in Germany
100. Genetic Analysis of MPO Variants in Four Psoriasis Subtypes in Patients from Germany
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.